基于一项药物监督研究,对rimegepant的营销后安全性存在担忧
Jia-Ling Hu1, Jing-Ying Wu1, Shan Xu1
1Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
The journal of headache and pain
|October 7, 2024
概括
这项研究发现了rimegepant的新潜在不良事件,包括胃肠道和神经系统的影响. 现实世界的数据分析突出了患者人口统计和药物组合之间的安全差异.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 现实世界的证据.
背景情况:
- 里米格佩邦 (Rimegepant) 是一种在临床环境中使用的药物.
- 全面的安全性评估对于在现实世界中理解药物效应至关重要.
- 美国食品和药物管理局的不良事件报告系统 (FAERS) 数据库为药物监测提供了有价值的数据.
研究的目的:
- 在现实临床环境中全面评估rimegepant的安全性.
- 为了确定与rimegepant相关的潜在新不良事件.
- 分析rimegeepant不良事件的人口统计和同时服用药物的相关差异.
主要方法:
- 从2020年第二季度到2023年第一季度的FAERS数据的回顾性分析.
- 基组分析和描述性统计的rimegepant相关的不良事件.
- 应用四种不相称性分析方法来检测不良事件信号.
主要成果:
- 确定了10,194个不良事件,里米格潘特作为主要的可疑药物.
- "一般性疾病和注射部位状况"是一个重要的系统器官类.
- 发现的新不良事件包括投射性吐,勃起和运动恶心;大多数报告来自消费者,主要是女性患者,同时使用复杂的药物.
结论:
- 与rimegepant相关的潜在新不良事件的初步识别,特别是影响胃肠道,神经和免疫系统.
- 在不同年龄组和性别中观察到与rimegepant相关的不良事件的显著差异.
- 同时使用药物的复杂性在临床实践中需要特别注意.
关键词:
不良事件是不良事件.数据挖掘是一种数据挖掘.公平的人是公平的.药物监督 药物监督 药物监督里姆·格佩潘特 (Rimegepant) 的意思就是说性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.9K
07:49Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
11.5K
相关概念视频
01:19Pharmacovigilance
784
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
784
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:20Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
151
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
151